Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies

Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib. Supplementary material. Medical history of the patient in Cohort 1 who experienced possible drug-related Grade 5 neutropenic sepsis. Supplementary Table 1. Patient disposition by dose level and diagnosis (safety population).† Supplementary Table 2. Exposure to talazoparib (safety population).